Artal Group S.A.

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), Artal Group S.A. reported 2 stock positions worth $714.6 million. Its top holding was Cava (CAVA) at 78.1% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 21.9%). Its holdings were unchanged from Q3 2025.

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001053906
Portfolio Value
$714.6M (Q4 2025)
SEC Filing
0001053906-26-000003 ↗ filed Feb 12, 2026

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.9B Q1 2024 Q2 2024: $3.9B Q2 2024 Q3 2024: $2.4B Q3 2024 Q4 2024: $1.2B Q4 2024 Q1 2025: $884.2M Q1 2025 Q2 2025: $930.2M Q2 2025 Q3 2025: $758.2M Q3 2025 Q4 2025: $714.6M $714.6M Q4 2025 Q1 2026: $1.0B Q1 2026 Q2 2026: $931.1M Q2 2026

Holdings 2 stocks · $714.6M
CAVA Cava Group Inc. 78.09% 9,507,990 $558.0M No change
LXRX Lexicon Pharmaceuticals Inc. 21.91% 136,180,481 $156.6M No change

Portfolio Sells Q3 2025 → Q4 2025
None this quarter.

Portfolio Buys Q3 2025 → Q4 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$931.1MCAVA, LXRX
Q1 2026 2$1.0BCAVA, LXRX
Q4 2025 2$714.6MCAVA, LXRX
Q3 2025 2$758.2MCAVA, LXRX
Q2 2025 2$930.2MCAVA, LXRX
Q1 2025 2$884.2MCAVA, LXRX
Q4 2024 2$1.2BCAVA, LXRX
Q3 2024 2$2.4BCAVA, LXRX
Q2 2024 108$3.9BCAVA, LXRX, SRRK, KYMR, MORF
Q1 2024Amended 107$3.9BCAVA, LXRX, SRRK, KYMR, ARWR